CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals (VRTX)
announced Health Canada has granted Marketing Authorization for the expanded use
of TRIKAFTA for the treatment of cystic fibrosis in patients aged 2 years and
older who have a mutation in the cystic fibrosis transmembrane conductance
regulator gene that is responsive based on clinical and/or in vitro data.
TRIKAFTA was previously approved for use in people with CF aged 2 years and
older with at least one F508del mutation and is now approved for 152 additional
mutations.

The company noted that the label update is based on data from multiple sources,
including a 24-week randomized placebo-controlled double-blind study in patients
aged 6 years and older who had at least one qualifying non-F508del mutation to
evaluate the safety and efficacy of TRIKAFTA.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX